September 2020 in “Scientific periodicals of Ukraine” "Flosin – Prostamol Uno" effectively manages BPH symptoms with fewer side effects.
91 citations
,
March 1994 in “Journal of Investigative Dermatology” 16 citations
,
June 2018 in “JAAD case reports” A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
89 citations
,
February 1993 in “Journal of Medicinal Chemistry” New compounds called benzoquinolinones may treat conditions linked to excess DHT.
May 2021 in “The FASEB Journal” The research gives new understanding on how human steroid 5α-reductases work and how drugs like finasteride inhibit them, which could help in creating new drugs.
63 citations
,
May 2011 in “Clinical cancer research” The topical inhibitor CUR61414 was not effective in treating basal cell carcinoma in human trials.
May 2022 in “Current Enzyme Inhibition” Compound 7b is a promising candidate for treating benign prostatic hyperplasia and prostate cancer.
1 citations
,
July 2012 in “Der Urologe” Finasteride effectively reduces prostate size and symptoms in most BPH patients.
40 citations
,
April 1999 in “Drugs” Finasteride treats enlarged prostate, improves urinary flow, but may cause sexual side effects.
20 citations
,
February 2002 in “Expert Opinion on Therapeutic Patents” New research is needed to create better drugs that block the enzyme responsible for conditions like male baldness and prostate enlargement.
1 citations
,
November 2023 in “BMC chemistry” Tadalafil and Finasteride may help treat aggressive melanoma.
Farudodstat may effectively treat alopecia areata by protecting hair follicles without harmful effects.
18 citations
,
October 2010 in “Bioorganic & Medicinal Chemistry Letters” New hybrid compound found to effectively prevent hair loss.
47 citations
,
June 2009 in “Journal of Biological Chemistry” Finasteride helps treat hair loss and prostate enlargement by blocking a specific enzyme.
November 2005 in “The Journal of Urology”
1 citations
,
January 2013 in “MedChemComm” PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
Finasteride affects prostate development differently in male and female Mongolian gerbils.
March 2026 in “Frontiers in Bioscience-Elite” Duloxetine, escitalopram, and finasteride may be effective against bacteria and fungi.
January 2000 in “Cambio 16” Bcl-2 affects hair growth and pigmentation by controlling cell death.
July 2018 in “DOAJ (DOAJ: Directory of Open Access Journals)” The new gel formula could improve the delivery of a hair loss treatment through the skin and might be an alternative to taking it by mouth.
17 citations
,
May 1998 in “Steroids” Researchers developed a model to predict how well certain compounds can block an enzyme related to hair loss and prostate issues, suggesting a 50 mg dose of finasteride might be effective based on lab and body data.
30 citations
,
October 2020 in “Nature Communications” Finasteride irreversibly affects human steroid 5α-reductase 2, providing insight into its catalytic mechanism and disease-related mutations.
4 citations
,
June 2025 in “Frontiers in Immunology” BAFF-targeted therapies can reduce autoimmune disease activity, but more research is needed for precise treatments.
April 2025 in “European Journal of Pharmaceutics and Biopharmaceutics” The new drug delivery system improves bicalutamide skin retention for better treatment of hair loss.
7 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism”
1 citations
,
April 2019 in “Journal of Investigative Dermatology” VB1953 gel significantly reduced acne and resistant bacteria in patients who didn't respond to clindamycin.
4 citations
,
August 2010 in “Acta Biologica Hungarica” New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.
March 2025 in “Carbohydrate Polymer Technologies and Applications” The new method improves finasteride's effectiveness for hair loss treatment.
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.